This follows a basic rule in the drug approval process - give the FDA what they want:
"Ariana is one of the first companies to implement the new FDA draft enrichment guidelines for patient stratification and trial enrichment"
and
"KEM® is the only FDA-tested technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine."